2015 American Transplant Congress
Assessment of IgG Subclass Significance for Early Graft Rejection and Long-Term Survival in HLA-Antibody Incompatible Renal Transplantation: Multivariate Approach
Donor HLA specific antibodies (DSA) can cause acute rejection and graft lost after renal transplantation. However neither the damaging antibody types, nor their acceptable levels…2015 American Transplant Congress
DSA MFI Does Not Predict Late Antibody-Mediated Rejection Lesions Or Gene Expression Changes in Kidney Transplants
BACKGROUND: It is unclear whether donor-specific HLA antibody (DSA) levels at the time of a clinically-indicated biopsy can be predictive of the degree of antibody-mediated…2015 American Transplant Congress
Cognate Events in Antibody- Vs. T Cell-Mediated Rejection: A Molecular Perspective
AIM: The cognate event in antibody-mediated rejection (ABMR) is NK cell FcR engagement; T cell mediated rejection (TCMR) uses TCR engagement. Understanding the molecular changes…2015 American Transplant Congress
Measuring Affinity of Polyclonal HLA-Specific Antibodies in Highly Sensitised Cases Can Serve as an Additional Biomarker to Guide Direct Transplantation
Significant numbers of patients on transplant waiting lists in the UK are sensitised (43%). Direct transplantation across these HLA-specific antibodies using risk stratification strategies are…2015 American Transplant Congress
Number of Antigen Targets: A Key Parameter for Accurate Flow Cytometry Crossmatch Interpretation of Weak DSA
BACKGROUND: Flow cytometry crossmatch (FCXM) results are used to assess the safety of a transplant across pre-existing DSA. The number of targets on donor cells…2015 American Transplant Congress
Part II: Rates and Determinants of Progression for De Novo Donor-Specific Antibody Mediated Kidney Allograft Injury
The development of de novo donor-specific antibody (dnDSA) is an independent predictor of allograft loss in renal transplantation. Rates and determinants of clinical pathologic progression…2015 American Transplant Congress
Should Current IVIg Preparations Containing High Titers of Anti-HLA-I/-II IgG be Used for Lowering the Anti-HLA IgG in Sensitized Pre-Transplant Patients and Allograft Recipients?
HLA antibodies, Terasaki Foundation Laboratory, Los Angeles, CA.
Sera of non-alloimmunized individuals contain anti-HLA-I & -II IgG. Therefore it is reasonable expect HLA-I/-II reactivity of Intravenous Immunoglobulin (IVIg). However, the titers at which…2015 American Transplant Congress
Improving the Predictive Value of the Virtual Crossmatch: Is the C1Q Assay Needed?
The criteria for reporting unacceptable HLA antigens of renal transplant candidates differ greatly between transplant centers. In the attempt to refine these criteria, the experience…2015 American Transplant Congress
Clinical and Immunologic Risk Factors Associated With Donor-Specific Antibody (DSA) Formation Following Renal Transplantation
Background: De novo DSA formation is emerging as an important risk factor for adverse graft outcomes following renal transplantation. Specific pretransplant risk factors for DSA…2015 American Transplant Congress
De Novo DSA Would Not Necessarily Cause Graft Rejection After Renal Transplantation: Characteristics of DSA Developing Biopsy-Proven Chronic Antibody-Mediated Rejection
Kidney Center, Nagoya Daini Red Cross Hospital, Nagoya, Japan.
Introduction:De novo donor-specific HLA antibodies (dn DSA) production after renal transplantation has been reported to be associated with chronic antibody mediated rejection (CAMR), which leads…
- « Previous Page
- 1
- …
- 40
- 41
- 42
- 43
- 44
- …
- 47
- Next Page »